Spago Nanomedical AB (SPAGO) — Cash Flow-to-Debt Ratio
Spago Nanomedical AB (SPAGO) has a Cash Flow-to-Debt Ratio of -1.04x as of December 2025, meaning its operating cash flow of Skr-6.19 Million could theoretically repay -1% of its total liabilities (Skr5.94 Million) in one year. Check Spago Nanomedical AB total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Spago Nanomedical AB Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Spago Nanomedical AB across 15 annual periods. Also explore SPAGO asset base for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Spago Nanomedical AB (2011–2025)
Year-by-year debt coverage analysis for Spago Nanomedical AB. For market capitalisation and broader financial context, see Spago Nanomedical AB (SPAGO) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.77x | Skr-28.30 Million | Skr5.94 Million | ▲ +12.7% |
| 2024 | -5.46x | Skr-34.67 Million | Skr6.35 Million | ▼ -41.9% |
| 2023 | -3.85x | Skr-44.91 Million | Skr11.67 Million | ▲ +11.3% |
| 2022 | -4.34x | Skr-38.19 Million | Skr8.80 Million | ▲ +16.9% |
| 2021 | -5.22x | Skr-35.57 Million | Skr6.81 Million | ▲ +12.5% |
| 2020 | -5.97x | Skr-18.77 Million | Skr3.15 Million | ▲ +18.5% |
| 2019 | -7.32x | Skr-21.29 Million | Skr2.91 Million | ▼ -185.3% |
| 2018 | -2.57x | Skr-10.51 Million | Skr4.10 Million | ▼ -26.5% |
| 2017 | -2.03x | Skr-7.73 Million | Skr3.81 Million | ▼ -112.0% |
| 2016 | -0.96x | Skr-7.86 Million | Skr8.22 Million | ▼ -67.0% |
| 2015 | -0.57x | Skr-5.34 Million | Skr9.33 Million | ▼ -88.0% |
| 2014 | -0.30x | Skr-5.95 Million | Skr19.53 Million | ▲ +22.4% |
| 2013 | -0.39x | Skr-7.74 Million | Skr19.69 Million | ▼ -642.6% |
| 2012 | -0.05x | Skr-601.00K | Skr11.36 Million | ▼ -138.2% |
| 2011 | -0.02x | Skr-276.00K | Skr12.42 Million | — |